Annals of Oncology Advance Access originally published online on July 13, 2007
Annals of Oncology 2007 18(8):1314-1321; doi:10.1093/annonc/mdm011
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
reviews |
Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations
1 Hôpital Pitié-Salpêtrière, Paris
2 Université Paul-Sabatier and Institut Claudius-Regaud, Toulouse, France
3 Memorial Sloan-Kettering Cancer Center, New York, NY, USA
4 University Hospital Gasthuisberg, Leuven, Belgium
5 Murray Valley Private Hospital, Wodonga, Australia
6 Clinique de Genolier, Geneva, Switzerland
* Correspondence to: Dr M. S. Aapro, Doyen IMO Clinique de Genolier, 1 route du Muids, 1272 Genolier, Switzerland. Tel: +41-223669106; Fax: +41-223669131; E-mail: maapro{at}genolier.net
Background: Elderly cancer patients commonly have renal function decline. This warrants particular caution during the administration of renally excreted cancer drugs or those with established nephrotoxicity.
Design: An International Society for Geriatric Oncology task force was formed to discuss treatment recommendations for this group of patients.
Results: Before drug therapy, the assessment and optimization of hydration status and evaluation of renal function is required. Serum creatinine alone is insufficient as a means of evaluating renal function, and creatinine clearance should at least be calculated in every patient by the abbreviated modification of diet in renal disease or Cockcroft-Gault equations. In the extremes of obesity and cachexia and at very high and low creatinine values, no single tool is really accurate. In these patients, the best estimate of glomerular filtration rate is provided by direct methods such as 51Cr-EDTA or inulin measurement. Within each drug class, preference may be given to agents less likely to be influenced by renal clearance, which are minimally nephrotoxic, or for which appropriate methods of prevention for renal toxicity exist. Coadministration of known nephrotoxic drugs should be avoided or minimized.
Conclusions: Future trials should be designed to present data in a way that allows evaluation of the contribution of renal function to toxicity and efficacy.
Key words: cancer, clinical practice recommendations, creatinine clearance, elderly, renal insufficiency, SCr
Received for publication October 11, 2006. Revision received November 21, 2006. Accepted for publication November 27, 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. G. Pallis, C. Gridelli, J. P. van Meerbeeck, L. Greillier, U. Wedding, D. Lacombe, J. Welch, C. P. Belani, and M. Aapro EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population Ann. Onc., August 28, 2009; (2009) mdp360v1. [Abstract] [Full Text] [PDF]
|
|